Comorbidities among patients with Gaucher disease
| GD related . | ERT related . | SRT related . |
|---|---|---|
| Amyloidosis | Class effect: | Class effect: |
| Cholelithiasis | ASIA/reactive arthritis | GI symptoms (eg, diarrhea, heartburn) |
| Celiac disease | Diabetes mellitus type 2 | Headache |
| Hashimoto thyroiditis | Hyperlipidemia | Drug specific: |
| Hepatocellular carcinoma | Metabolic syndrome | Cardiotoxicity |
| Immune thrombocytopenia | NAFLD/NASH | Cognitive impairment |
| Liver cirrhosis | Polyneuropathy | Drug–drug interaction |
| Lymphomas | Pulmonary hypertension | NSVT |
| MGUS | Weight gain | Peripheral neuropathy |
| Multiple myeloma | Drug-specific: | Tremor |
| Myelodysplastic syndrome | Allergy/hypersensitivity | Weight loss |
| Parkinson disease | ||
| Portal hypertension | ||
| Pulmonary hypertension | ||
| Recurrent abortions | ||
| Uveitis | ||
| Vitamin B12 deficiency | ||
| To be determined: gout, hypothyroidism, vitamin D deficiency |
| GD related . | ERT related . | SRT related . |
|---|---|---|
| Amyloidosis | Class effect: | Class effect: |
| Cholelithiasis | ASIA/reactive arthritis | GI symptoms (eg, diarrhea, heartburn) |
| Celiac disease | Diabetes mellitus type 2 | Headache |
| Hashimoto thyroiditis | Hyperlipidemia | Drug specific: |
| Hepatocellular carcinoma | Metabolic syndrome | Cardiotoxicity |
| Immune thrombocytopenia | NAFLD/NASH | Cognitive impairment |
| Liver cirrhosis | Polyneuropathy | Drug–drug interaction |
| Lymphomas | Pulmonary hypertension | NSVT |
| MGUS | Weight gain | Peripheral neuropathy |
| Multiple myeloma | Drug-specific: | Tremor |
| Myelodysplastic syndrome | Allergy/hypersensitivity | Weight loss |
| Parkinson disease | ||
| Portal hypertension | ||
| Pulmonary hypertension | ||
| Recurrent abortions | ||
| Uveitis | ||
| Vitamin B12 deficiency | ||
| To be determined: gout, hypothyroidism, vitamin D deficiency |
ASIA, autoimmune syndrome induced by adjuvant; bold, most common GD-related comorbidities; ERT, enzyme replacement therapy; GD, Gaucher disease; GI, gastrointestinal; MGUS, monoclonal gammopathy of undetermined significance; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NSVT, nonsustained ventricular tachycardia; SRT, substrate reduction therapy.